LRRK2 and Parkinson disease: MiR-6800 level was significant higher in L2NMC (LRRK2 non-manifesting carriers) than in L2PD (LRRK2 carrier with symptomatic PD) (Soto et al., 2023), which implies that miR-6800 have a significantly protective effect on PD.